Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 331.5 INR 2.6% Market Closed
Market Cap: 398B INR
Have any thoughts about
Biocon Ltd?
Write Note

Biocon Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biocon Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Biocon Ltd
NSE:BIOCON
Depreciation & Amortization
-â‚ą16.5B
CAGR 3-Years
-29%
CAGR 5-Years
-27%
CAGR 10-Years
-23%
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Depreciation & Amortization
-â‚ą1.4m
CAGR 3-Years
7%
CAGR 5-Years
20%
CAGR 10-Years
20%
Transgene Biotek Ltd
BSE:526139
Depreciation & Amortization
-â‚ą924.9k
CAGR 3-Years
79%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Depreciation & Amortization
-â‚ą70.1m
CAGR 3-Years
-1%
CAGR 5-Years
-10%
CAGR 10-Years
-7%
Hester Biosciences Ltd
NSE:HESTERBIO
Depreciation & Amortization
-â‚ą158.3m
CAGR 3-Years
-6%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Panacea Biotec Ltd
NSE:PANACEABIO
Depreciation & Amortization
-â‚ą359.6m
CAGR 3-Years
7%
CAGR 5-Years
14%
CAGR 10-Years
N/A
No Stocks Found

Biocon Ltd
Glance View

Market Cap
398B INR
Industry
Biotechnology

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

BIOCON Intrinsic Value
455.48 INR
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Biocon Ltd's Depreciation & Amortization?
Depreciation & Amortization
-16.5B INR

Based on the financial report for Sep 30, 2024, Biocon Ltd's Depreciation & Amortization amounts to -16.5B INR.

What is Biocon Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-23%

Over the last year, the Depreciation & Amortization growth was -17%. The average annual Depreciation & Amortization growth rates for Biocon Ltd have been -29% over the past three years , -27% over the past five years , and -23% over the past ten years .

Back to Top